Abiopharma

🔍 Edmondson Frazor Titus III (Executive)

Company: Zai Lab Ltd (ZLAB)

Report Date: 2026-06-25

Detailed Transactions and Holdings:

• Acquired 14,600 shares of American Depositary Shares (Direct)
  Date: 2026-06-25 | Code: M | equity_swap_involved: false | shares_owned_after: 34,449.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 4,103 shares of American Depositary Shares at $17.461 per share (Direct)
  Date: 2026-06-26 | Code: S | equity_swap_involved: false | shares_owned_after: 30,346.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 14,600 shares of Restricted Share Units (Derivative)
  Date: 2026-06-25 | Code: M | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3, F5, F5, F1

Footnotes:

• F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
• F2: ADSs acquired upon vesting of Restricted Share Units ("RSUs").
• F3: Each RSU represents a contingent right to receive one ADS.
• F4: These ADSs were sold automatically to cover taxes upon vesting of RSUs.
• F5: The RSUs vested in equal annual installments over four years beginning on 06/25/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.